Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study

Primary tabs

SCIENCE
Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study
Key Take-Away: 

According to this research, the most effective pharmacotherapy for different subgroups of fibromyalgia patients can be deduced from doing pretests of sympathetic nervous system (SNS) function in untreated fibromyalgia patients which may serve as a proficient biomarker. Also, pregabalin application lead to significant reduction in multiple fatigue-related symptoms, along with improvement in pain and sleep quality.

Pregabalin, an approved treatment for fibromyalgia (FM), has been shown to decrease sympathetic nervous system (SNS) activity and inhibit sympathetically maintained pain, but its effects on exercise responses have not been reported. 

ABSTRACT: 
Background: 

Pregabalin, an approved treatment for fibromyalgia (FM), has been shown to decrease sympathetic nervous system (SNS)

activity and inhibit sympathetically maintained pain, but its effects on exercise responses have not been reported. 

Methods: 

Using a randomized double-blind crossover design, we assessed the effect of 5 weeks of pregabalin (versus placebo) on acute cardiovascular and subjective responses to moderate exercise in 19 FM patients.

Blood pressure (BP), heart rate (HR), and ratings of perceived exertion (RPE) during exercise and ratings of pain, physical fatigue, and mental fatigue before, during, and for 48 hours after exercise were compared in patients on pregabalin versus placebo and also versus 18 healthy controls. 

Results: 

On placebo, exercise RPE and BP were significantly higher in FM patients than controls (p<0.04). Pregabalin responders (n=12), defined by patient satisfaction and symptom changes) had significantly lower exercise BP, HR, and RPE on pregabalin versus placebo (p<0.03) and no longer differed from controls (p>0.26).

Cardiovascular responses of nonresponders (n=7) were not altered by pregabalin. In responders, pregabalin improved ratings of fatigue and pain (p<0.04), but negative effects on pain and fatigue were seen in nonresponders.

Conclusion: 

These preliminary findings suggest that pregabalin may normalize cardiovascular and subjective responses to exercise in many FM patients.

Pain Research and Treatment 2015
Log in or register to post comments